News

Basel, Switzerland. May 9, 2023, 9am CET BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today, that the first patient has been dosed in a multicenter Phase 2 clinical trial […]

Basel, Switzerland. January 31, 2023, 9am CET BioVersys AG announces first patient dosed in Phase 2a clinical trial with BVL-GSK099 BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today, that

Basel, Switzerland. January 5, 2023, 1pm CET BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investment BioVersys AG, a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and

Basel, Switzerland. June 21, 2022, 9am CEST BioVersys AG announces successful completion of Phase I clinical trials with BVL-GSK098 BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today the successful

Basel, Switzerland. June 8, 2022, 9am CEST BioVersys AG announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR therapies BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation, announced

BioVersys AG announces successful completion of three Phase 1 of clinical trials with BV100 BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today the successful completion of three Phase I

Basel, Switzerland. January 07, 2021, 2pm CEST BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today that Marc Gitzinger, Chief Executive Officer at BioVersys, will present a company overview

Basel, Switzerland. November 3, 2021, 9am CEST BioVersys AG doses first subjects in multiple ascending dose and renal impairment Phase 1 clinical trials with BV100 BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and

Basel, Switzerland. August 24, 2021, 9am CEST BioVersys AG appoints Dr. William Jenkins as special advisor and board member elect BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today

Basel, Switzerland. July 6, 2021, 9am CEST BioVersys presents update on its innovative antimicrobial pipeline with three oral and six poster presentations at ECCMID, July 9-12, 2021 BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance